Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Model Lists of Essential Medicines

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Approximately 38.4 million people in the US are affected by diabetes

- PMLiVE

Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

The companies will aim to discover and develop new therapeutics for the group of disorders

- PMLiVE

Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition

The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD

- PMLiVE

NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

- PMLiVE

Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

The immune-mediated disease affects more than 2.9 million people worldwide

- PMLiVE

Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

- PMLiVE

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

- PMLiVE

Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

Cardiovascular diseases result in an estimated 17.9 million global deaths each year

- PMLiVE

Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links